{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037574","form_type":"8-K","ticker":"INDP","cik":"0001857044","company_name":"Indaptus Therapeutics, Inc.","filed_at":"2026-08-13T11:30:16+00:00","discovered_at":"2026-08-13T11:35:00.261059+00:00","generated_at":"2026-08-13T11:35:31.078222+00:00","sec_items":["2.02","5.07","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Indaptus discontinues Decoy20 enrollment, no active clinical programs; Q2 net loss $1.8M","bullets":["Q2 2026 net loss $1.8M vs $5.2M in Q2 2025; six-month loss $4.3M vs $9.8M; EPS loss $0.02 vs $9.09.","Decoy20 enrollment discontinued; no participants remain in any clinical study; no active clinical development programs.","June 17, 2026 private placement: 20M shares at $0.60/share, $12.0M gross proceeds; cash+investments $11.6M at June 30.","R&D expenses down 83% to $0.4M (Q2) and $0.9M (six months); G&A down 37% to $1.4M (Q2).","Annual meeting elected David Natan, Tim Ruan, Dr. Johnny Fox Arrowsmith as Class II directors; approved 2026 equity plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037574","json":"https://secwatch.observer/filing/0001493152-26-037574.json","markdown":"https://secwatch.observer/filing/0001493152-26-037574.md","text":"https://secwatch.observer/filing/0001493152-26-037574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1857044/000149315226037574/0001493152-26-037574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1857044/000149315226037574/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:35:31.078222+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}